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ivalirudin is a short-acting direct thrombin inhibitor that is increasingly used for an-
ticoagulation during cardiac surgery in patients with heparin-induced thrombocyto-
penia (HIT).1 During cardiopulmonary bypass (CPB) with heparin anticoagulation,
aprotinin reduces hemostatic activation, inflammatory response, perioperative
blood loss, and transfusion requirements. The current investigation was performed to assess
the effects of aprotinin when bivalirudin is used for anticoagulation during CPB.
Materials and Methods
After approval by the German Ministry for Drug Safety and the local ethics committee and
informed consent was obtained, 14 patients scheduled for first-time elective coronary artery
bypass grafting (CABG) were enrolled in this prospective single-center investigation. Patients
were randomized to 2 groups with 7 patients each: 1 group with bivalirudin anticoagulation only
and 1 group with bivalirudin and aprotinin. All patients had normal renal function, a left ven-
tricular ejection fraction of more than 30%, and antiplatelet therapy discontinued 5 days before
surgery. Bivalirudin dosing and CPB management were performed as described before using
closed CPB systems without cardiotomy suction.2 Aprotinin was given according to a high-
dose protocol with 2 3 106 kallikrein inhibiting units (KIU) as patient bolus, 2 3 106 KIU
in the CPB priming solution, and continuous infusion of 0.5 3 106 KIU during CPB. Packed
red blood cell concentrates were transfused when the hemoglobin level was less than 8 g/dL.
The transfusion of fresh-frozen plasma and platelets was based on the physicians’ decision.
Samples for measurement of bivalirudin concentrations were obtained after the bolus was given
and at intervals of 15 minutes during CPB, at intervals of 5 minutes until 1 hour after CPB, and
at intervals of 15 minutes during the following hour. Bivalirudin concentrations were analyzed
with high-performance liquid chromatography. Samples for assessment of markers of hemo-
static activation (fibrinopeptide A and prothrombin fragment 112) and inflammation (interleu-
kin 6 and myeloperoxidase) were obtained 5 minutes after the bivalirudin bolus was given
(before initiation of CPB) and after termination of the bivalirudin infusion, shortly before ter-
mination of CPB. Samples were analyzed with standard enzyme-linked immune assays. Statis-
tical analysis was performed using the Student t, Wilcoxon rank-sum, and paired Wilcoxon
signed-rank tests.
Results
There were no differences regarding patients’ demographic data, duration of CPB, or surgery
(Table 1). The clinical course of all patients was uneventful. In control patients treated only
with bivalirudin, there was a moderate increase in markers of hemostatic activation and inflam-
matory response during CPB. The administration of high-dose aprotinin did not influence biva-
lirudin pharmacokinetics, hemostatic activation, and inflammatory response, but there was
a significant reduction of perioperative blood loss and a marked trend toward lower transfusion
requirements (Table 1; Figure 1).
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CABG 5 coronary artery bypass grafting
CPB 5 cardiopulmonary bypass
HIT 5 heparin-induced thrombocytopenia
KIU 5 kallikrein inhibiting unit
Discussion
The elimination of bivalirudin ismainly achieved by proteolytic cleav-
age.Because aprotinin is a proteinase inhibitor, concernsmaybe raised
that high concentrations of this agent may prolong bivalirudin half-life
and thereby increase the risk of hemorrhage. In a previous pilot inves-
tigation using a different protocol for bivalirudin and a half-dose apro-
tinin regimen, no impact of aprotinin on bivalirudin pharmacokinetics,
blood loss, and transfusion requirements was noted.3 Our current data
show that a high-dose aprotininprotocoldoes not affect the pharmacol-
ogy of bivalirudin. Moreover, the administration of aprotinin does not
attenuate the moderate hemostatic activation and inflammatory re-686 The Journal of Thoracic and Cardiovascular Surgery c Masponse observed during bivalirudin anticoagulation of CPB. How-
ever, even in this small number of patients, the administration of
aprotinin according to the high-dose protocol resulted in a highly sig-
nificant decrease in perioperative blood loss and a marked trend to-
ward a reduction of transfusions.
Aprotinin is one of the most effective drugs to reduce perioper-
ative blood loss and transfusion requirements in patients undergo-
ing CPB procedures with heparin anticoagulation. Recent studies
associated the use of aprotinin with increased myocardial infarc-
tion, renal failure, and 5-year mortality when given during CPB
with heparin anticoagulation and protamine reversal in patients un-
dergoing elective CABG.4,5 These results may promote the more
cautious use of aprotinin, particularly in low-risk patients undergo-
ing CABG. However, although the current investigation was not
powered to assess patient outcomes in this regard, the observed re-
duction of blood loss and transfusions in our patients undergoing
on-pump CABG with bivalirudin anticoagulation remains impres-
sive. The effects of drugs influencing the hemostatic system ob-
served in patients without HIT cannot automatically be translated
to patients with HIT. Nevertheless, in view of the current data,
we believe that in the high-risk population of patients with HIT,TABLE 1. Clinical and laboratory data
Bivalirudin
(n 5 7)
Bivalirudin 1 aprotinin
(n 5 7) P
Baseline characteristics
Age 63.0 6 7.0 61.7 6 9.1 .70
Gender, male % 85.7 85.7 1.0
Weight (kg) 88.7 6 15.0 89.0 6 14.9 .85
CPB 1 surgery
Time on CPB (min) 86.4 6 21.4 93.0 6 28.2 .57
Duration of surgery (min) 213.9 6 38.4 214.7 6 54.8 .85
Blood loss 1 transfusions
Mean blood loss 2 h postsurgery (mL) 454 6 304 96 6 37 .002
Mean blood loss 12 h postsurgery (mL) 959 6 472 274 6 53 .002
Any transfusions (%) 71.4 42.9 .59
PRBC (%) 57.1 28.6 .59
Mean no. of units in patients with PRBC 3.3 6 2.6 2 6 0 .62
Inflammation 1 hemostatic activation
MPO (pM) pre-CPB 66.8 6 136.7 69.4 6 153.0 .65
MPO (pM) post-CPB 63.5 6 88.4 76.7 6 133 .95
Pre vs post-CPB P value (within group) .56 .237
IL6 (pg/mL) pre-CPB 13.0 6 4.7 15.9 6 11.4 .85
IL6 (pg/mL) post-CPB 72.1 6 49.4 83.6 6 42.1 .57
Pre vs post-CPB P value (within group) .018 .028
FPA (ng/mL) pre-CPB 20.6 6 19.6 14.2 6 8.1 .85
FPA (ng/mL) post-CPB 26.0 6 16.6 32.6 6 19.6 .41
Pre vs post-CPB P value (within group) .091 .063
PF 112 (pM) pre-CPB 476 6 264 222 6 54 .025
PF 112 (pM) post-CPB 512 6 251 418 6 211 .37
Pre vs post-CPB P value (within group) .128 .043
CPB, Cardiopulmonary bypass; PRBC, packed red blood cell concentrates;MPO, myeloperoxidase; IL, interleukin; FPA, fibrinopeptide A; PF 112, prothrombin
fragment 112.rch 2008
Brief CommunicationsFigure 1. Group 1 5 bivalirudin; Group II 5 bivalirudin 1 aprotinin.high-dose aprotinin may be considered as an adjunctive agent dur-
ing CPB anticoagulation with bivalirudin. This applies particularly
to complex procedures with a high risk of increased perioperative
bleeding.
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